Receipt of live, attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab \r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of a live vaccine within 30 days prior to registration for protocol therapy
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Patients must not have received a live attenuated vaccination within 28 days prior to sub-study registration
Patients are ineligible if administration of a live, attenuated vaccine within 4 weeks before randomization
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab; Note: influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 28 days prior to randomization or at any time during the study
Patients must not have received of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Patient must not receive live, attenuated influenza vaccine within 4 weeks prior to registration or at any time during the study and until 5 months after the last dose of atezolizumab
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Patients receiving live/attenuated vaccinations within 4 weeks prior to registration are not eligible
17. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving TAB001;
Received a live-virus vaccination within 30 days of planned treatment start.
Administration of live vaccine within 4 weeks prior to study entry
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Treatment with a live, attenuated vaccine within 4 weeks before initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Have received a live-virus vaccine within 30 days prior to planned treatment start.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study therapy.
Received live-virus vaccination within 30 days (seasonal flu vaccine allowed if non-live virus)
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of live vaccine within 28 days of planned first dose of TVEC
SAFETY RUN-IN: Has received a live vaccine within 30 days prior to the first dose of trial treatment
RANDOMIZED PHASE II CLINICAL TRIAL: Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of study drug; seasonal influenza vaccination is permitted excluding the nasal spray formulation
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Received a live vaccine within 30 days of the first dose of study medication
Administration of a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Has received a live vaccine within 28 days of planned start of study therapy
Has received a live vaccine within 30 days prior to the first dose of trial drug.
Has received a live vaccine within 28 days of planned start of study therapy
Has received a live vaccine within 30 days prior to the first dose of study therapy
Has received a live-virus vaccine within 30 days prior to first dose of study medication.
Receipt of a live vaccine within 30 days of start of study treatment
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Has received a live vaccine within 30 days prior to the first dose of study therapy
Receipt of live attenuated vaccines (including, but not limited to: intranasal influenza vaccine [FluMist], measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], and typhoid vaccine) within 30 days before the first dose of study treatment
Administration of a live, attenuated vaccine within 28 days prior to randomization or anticipation that such vaccine will be required during the study. Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo.
Patients who have received a live vaccine within 30 days of the planned start of study therapy
Administration of a live attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
Must not have received a live vaccine within 30 days of planned start of the study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Have received a live vaccine within 30 days before the first dose of study treatment.
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days prior to first dose of study drug.
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
Received a vaccine within 7 days of first dose
Patients should not receive immunization with attenuated live vaccine within one week of study entry or during study period
Received live vaccine within 30 days of planned start of study medication
Received a live vaccine within 30 days of planned start of study medication
Has received a live vaccine within 28 days of planned start of study therapy
Treatment with therapeutic oral or intravenous (IV) antibiotics; or with a live, attenuated vaccine; or systemic immunosuppressive medication
Administration of a live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 or at any time during the study and for at least 5 months after the last dose of study drug
Has received a live-virus vaccination within 30 days of planned treatment start.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Received a live vaccine within 30 days of the first dose of treatment.
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study; inactivated vaccines (such as hepatitis A or polio vaccines) are permitted during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must no receive live attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 and for at least 12 weeks after the last dose
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Participants must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1, at any time during the study or 5 months after the last dose of atezolizumab
Received a live vaccine =< 30 days prior to registration
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Patients should not be vaccinated with live attenuated vaccines within 1 month of starting tremelimumab and durvalumab treatment; subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of both drugs
Patients should not receive immunization with attenuated live vaccine within one week of study entry or during study period
Immunization with any attenuated live vaccine within 1 week prior to initiating protocol-indicated treatment.
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.
Vaccinations with a live vaccine within 28 days prior to start of treatment or need for live vaccine at any time during study treatment.
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine ? 30 days prior to study registration
Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX, Fluzone) within 28 days or 14 days, respectively, of the first planned dose of ETBX vaccine
Has received a live vaccine within 30 days of planned start of study therapy
Vaccine administration of live vaccines within 28 days of enrollment
Has received a live vaccine within 30 days prior to the initiation of lymphodepletion.
Vaccination with a live vaccine < 28 days prior to the start of treatment
Live attenuated vaccinations 14 days prior to treatment
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Subjects, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
Has received a live vaccine within 28 days prior to registration
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Received live or attenuated vaccination within 28 days prior to the start of NMA-LD
Live vaccine within 4 weeks of the first dose of pembrolizumab and while on trial is prohibited
Has received a live vaccine within 30 days prior to the first dose of study drug
Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.
Vaccinated with live, attenuated vaccine within 4 weeks or as recommended by the product manufacturer prior to the first dose, during treatment, or within 100 days of the last dose of JNJ-64407564
Live vaccination within the last 30 days
Has received a live vaccine within 30 days prior to the first dose of the trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette - Guérin (BCG), and typhoid vaccine.
GENERAL: Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study.
Received live vaccine within 28 days prior to enrollment
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Live vaccine ? 4 weeks prior to enrollment
Administration of a live vaccine within 4 weeks prior to study entry
Received any live vaccine within the last 30 days
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving study treatment
Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that a live, attenuated vaccine will be required during atezolizumab/placebo treatment or within 5 months after the last dose of atezolizumab/placebo
Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with avelumab or within 5 months after the last dose of avelumab\r\n* Attenuated live vaccines include but are not limited to:\r\n** Tuberculosis (Bacillus Calmette-Guerin [BCG])\r\n** Oral polio vaccine\r\n** Measles, mumps, rubella, alone or as part of measles/mumps/rubella vaccine (MMR)\r\n** Rotavirus\r\n** Yellow fever\r\n** Typhoid\r\n** Rabies vaccine should be utilized as recommended by an infectious disease specialist\r\n** Nasal flu vaccine
Received a live vaccine within 4 weeks prior to the start of study drug
Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen
Administration of a live, attenuated vaccine within 4 weeks before start of study treatment or anticipation that such a live, attenuated vaccine will be required during the study.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to start of study treatment or at any time during the study.
Has received a live vaccine within 30 days of planned start of trial therapy.
Receipt of a live vaccine =< 30 days prior to registration
Receipt of live attenuated vaccine within 30 days before the first dose of study treatment
The participant has received a live vaccine within 28 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette–Guerin (BCG), and typhoid vaccine; the use of the inactivated seasonal influenza vaccine (Fluzone) is allowed
Has received a live vaccine within 30 days of planned start of study therapy
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of live attenuated vaccination within 30 days prior to the first dose of IP; Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP
Has received a live vaccine within 30 days of first study procedure (apheresis)
Has received a live-virus vaccination within 30 days of planned treatment start
Patients who have received live, attenuated vaccine within 28 days prior to the first dose of PD-1 inhibitor.
Receipt of live attenuated vaccination within 30 days prior to the first dose of Vicinium or durvalumab
Receipt of live attenuated vaccine within 28 calendar days prior to the first study treatment is NOT permitted
Has received a live vaccine within 30 days prior to the first dose of study drug
Receipt of live attenuated vaccination within 30 days prior to first anticipated dose of nivolumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Received a live vaccine within 30 days prior to start of study treatment
Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment with atezolizumab or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to May in the Northern Hemisphere); patients must agree not to receive live attenuated influenza vaccine (e.g., FluMist) within 28 days prior to study treatment, during treatment, or within 90 days following the last dose of atezolizumab
Receipt of any prior therapy for CLL. Patients who have received “early intervention” with INVAC-1 vaccine against hTERT will be eligible provided all of the following exist: i) They had no response to the vaccine treatment (persistent CLL > 1% in bone marrow). ii) ·3 months have elapsed since the last dose of vaccine. iii) No residual toxicities attributable to the vaccine exist at the time of study enrollment. iv) The patient does not meet IWCLL criteria for requiring treatment.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab.
Patients must agree not to receive any live, attenuated influenza vaccine (e.g., FluMist) within 28 days prior to receiving study treatment, during treatment or within 5 months following the last dose of atezolizumab
Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Received a live vaccine =< 30 days prior to registration
Administration of a live vaccine within 6 weeks of first dose of study drug
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab (NOTE: If a vaccine is part of the treatment regimen for the indication under study, the vaccine is permitted)
Receipt of live attenuated vaccine within 30 days prior to study entry; enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumab
Has received a live vaccine within 30 days prior to first dose
Receipt of a live vaccine within 30 days of receipt of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Patients who received a live, attenuated vaccine =< 30 days before study treatment or are anticipated to require such a live attenuated vaccine are not eligible\r\n* NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 30 days prior to study registration or at any time during the study
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Administration of a live, attenuated vaccine within 4 weeks before cycle1 day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); subjects must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1 day 1 or at any time during the study
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Have received any live vaccination within 28 days of first dose of study drug
Any live, attenuated vaccine within 28 days prior to the first day of treatment or during study treatment, or unwillingness to avoid live, attenuated vaccines within 90 days following the last dose of atezolizumab
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Patients who have received a live vaccine within 30 days prior to the first dose of pembrolizumab
Receipt of a live virus vaccine =< 2 months prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab, or active infection
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Any live vaccine or non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab).
Received live vaccine within 28 days prior to enrollment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Has received a live vaccine within 30 days of planned start of study therapy
Vaccinated with live, attenuated vaccine(s) within 28 days prior to first dose of study drug
Received a live vaccine =< 30 days prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab OR tremelimumab.
Administration of a live, attenuated vaccine =< 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 4 weeks prior to cycle 1, day 1 or at any time during the study
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Administration of a live vaccine within 4 weeks prior to start of protocol therapy
Administration of a live, attenuated vaccine within 4 weeks for first study treatment
Has received a live vaccine within 30 days prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Vaccinated with live, attenuated vaccine within 4 weeks of first dose of study drug
Administration of a live, attenuated vaccine within 4 weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study or for 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March)\r\n* Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to enrollment, at any time during the study, or for 5 months after the last dose of atezolizumab
Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Subjects must not have received a live vaccine within 30 days prior to the first dose of study medication
Have received a live vaccine within 30 days prior to the first dose of trial treatment.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (e.g. live attenuated influenza vaccine [LAIV], measles/mumps/rubella vaccine [MMR], variola virus vaccine [VAR], zoster, yellow fever, etc.)
Received a live vaccine within 30 days of first protocol treatment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Patients who have received a live attenuated vaccine =< 30 days prior to registration are not eligible
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and 180 days after the last dose of investigational products)
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study and for 180 days after the last dose of both drugs)
Live attenuated vaccinations within 14 days prior to treatment
Receipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.
Patients who received a live, attenuated vaccine =< 28 days before study registration or are anticipated to require such a live attenuated vaccine are not eligible; NOTE: Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) =< 28 days prior to study registration or at any time during the study
Live attenuated vaccinations 14 days prior to treatment
Receipt of live attenuated vaccination within 30 days prior to study entry (or due to receive one within 30 days of receiving either MEDI4736 or tremelimumab)
Have received a live vaccine within 30 days before the first dose of study treatment.
Received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of a live vaccine within 30 days of study entry
Received live vaccine =< 30 days prior to registration
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for 180 days after the last dose of durvalumab)
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Has received a live vaccine 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live attenuated vaccine within 30 days prior to enrolling in the study.
Receipt of a live, attenuated vaccine within 28 days prior to the first dose of MEDI4736 and tremelimumab (NOTE: subjects, if enrolled, should not receive live vaccine during the study or for 180 days after the last dose of both drugs)
Receipt of live attenuated vaccination within 30 days prior to study entry or within 6 months of receiving MEDI4736 or MEDI + tremelimumab
Received a live virus vaccine within 30 days of planned start of therapy
Has received a live vaccine within 30 days of planned start of study therapy.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of live attenuated vaccination within 30 days prior to registration; NOTE: patients should also not receive such vaccination within 30 days of receiving durvalumab or tremelimumab
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received a live virus vaccine within 30 days of planned start of study treatment
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Subject has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Administration of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that such a live attenuated vaccine will be required during the study
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of live vaccine within 30 days prior to the first dose of trial treatment
Vaccination with a live vaccine within 28 days of the initiation of treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Live attenuated vaccination administered within 30 days prior to randomization.
Receipt of live attenuated vaccination within 30 days prior to receiving MEDI4736
Received a live vaccine within 30 days prior to first dose of study drug
Patient has received a live vaccine within 4 weeks prior to the first dose of treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Treatment with a live virus vaccine during the 3 months prior to baseline visit; no live vaccines will be allowed throughout the course of this study
Administration of a live vaccine within 6 weeks of first dose of study drug
Has received a live vaccine within 30 days of planned start of study therapy.
Have received any live vaccine within 14 days prior to first study drug administration.
Received a live attenuated vaccine within 28 days of first study dose, unable to take oral medications
Systemic steroid therapy within 28 days before vaccine administration
History of receiving a live vaccine 30 days prior to study treatment.
Receipt of any live vaccine within 4 weeks.
Has received a live vaccine within 30 days of planned start of study therapy
Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days after receiving the last dose of durvalumab.
Has received a live-virus vaccination within 30 days of planned treatment start.
Patients who have had a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment or at any time during the study
Administration of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such vaccine will be required during the study\r\n* Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo
Has received a live vaccine within 30 days prior to the first dose of study treatment
Received a live vaccine within 30 days prior to the first dose of study treatment.
Has received a live vaccine within 30 days of planned start of study therapy
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study. (Influenza vaccination should be given during influenza season only [approximately October to March]. Patients must not receive live, attenuated influenza vaccine [e.g., FluMist] within 4 weeks prior to cycle 1, day 1 or at any time during the study.)
Received live vaccine within 28 days prior to enrollment
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs; Note: Patients, if enrolled, should not receive live vaccine whilst receiving treatment with study drugs and up to 90 days after the last dose of study drugs
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days prior to the first dose of trial treatment.
Prior oncology vaccine therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live, attenuated vaccine within 30 days prior to study entry or the first dose of MEDI0457.\r\n* Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP.
Patient has received a live vaccine within 30 days prior to first dose
Has received a live vaccine within 30 days of planned start of study therapy
Administration of a live, attenuated vaccine within 30 days before week 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to week 1, day 1 or at any time during the study
Live, attenuated vaccine within 30 days prior to day 1 of protocol therapy
Is known to have received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Live vaccine within 30 days prior to treatment initiation.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days prior to study entry
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Patients who receive a live attenuated vaccine =< 28 days prior to registration are not eligible
Patients are excluded for receiving any non-oncology vaccine therapy used for prevention of infectious diseases for up to four weeks (28 days) prior to or after any dose of ipilimumab; NOTE: Patients are permitted to receive the seasonal influenza vaccine; if seasonal influenza vaccine is considered, killed vaccines should be recommended
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study and until 5 months after the last dose of atezolizumab
Administration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study
Patients who have received a live vaccine within 30 days prior to the radiation therapy
Immunization with a live/attenuated vaccine within 30 days of enrollment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first protocol treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
No prior vaccine therapy
Has received a live vaccine within 30 days of planned start of study therapy
Received a live vaccine =< 30 days of planned start of study therapy
Patients who have received any non-oncology live vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab/vaccine)
Received any live vaccine =< 30 days prior to registration
Received a live vaccine within 1 week prior to the first dose of study treatment
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Has received a live vaccine within 30 days prior to transplant admission
Received a live vaccine within 30 days of planned start of study medication
Has received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1).
Has received a live vaccine within 30 days of the first dose of study therapy
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a live vaccine within 30 days prior to the first dose of study medication
Live vaccine use within 30 days of first dose of study medication.
have received any recent (within 28 days prior to randomization) live virus vaccination
Administration of a live, attenuated vaccine within 4 weeks before first dosing or during the study.
Has received live, attenuated vaccine within 30 days prior to Study Day 1
Patient who requires live vaccine administration
The participant has received a live vaccine within 28 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine; the use of the inactivated seasonal influenza vaccine is allowed
Patients must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment
Has received a live vaccine within 30 days of planned start of study therapy.
Has received a live virus vaccine within 30 days of allocation.
Patients must not have received a live attenuated vaccination within 28 days prior to sub-study registration
Patients must not have received a live attenuated vaccination within 28 days prior to RE-TREATMENT registration
Subject has received a live, attenuated vaccine within 28 days prior to Cycle 1 Day 1;
Receipt of live, attenuated vaccine within 30 days prior to the first dose of durvalumab
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational product
Received a live-virus vaccination within 30 days of planned start of study medication.
Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study
Has received a live virus vaccine within 30 days of randomization.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP (NOTE: Subjects, if enrolled, should not receive live vaccine during the study and for 30 days after the last dose of durvalumab).
Received live vaccine within 28 days prior to enrollment
Has received live, attenuated vaccine within 30 days prior to Study Day 1
Live vaccine within 30 days of planned start of study drug
Treatment with a live vaccine or a live, attenuated vaccine (e.g., nasal spray of live attenuated influenza vaccine or FluMist®) within 4 weeks prior to initiation of study drug or anticipation that such treatment will be required during the study or within 5 months after the final dose of study drug
Received a live virus vaccine within 30 days of planned study start
Non oncology vaccine therapies for prevention of infectious disease (for example, seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of trial drug administration. Vaccination while on trial is also prohibited except for administration of inactivated vaccines (for example, inactivated seasonal influenza vaccine)
Has taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a live vaccine within 30 days before the first administration of study treatment
Vaccination with a live vaccine within 28 days prior to treatment
Has received a live virus vaccine within 30 days of planned start of trial treatment
Subjects who have received any non-oncology live vaccine therapy used for prevention of infectious diseases for up to 28 days prior to or after the initiation of treatment in this study
Has received a live-virus vaccination within 30 days of planned treatment start
Receipt of a live vaccine within 30 days before the first dose of study treatment.
Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study, or up to 5 months following the anticipated last dose of atezolizumab
Subject has received a live virus vaccine within the previous 8 weeks.
Administration of a live, attenuated vaccine within 4 weeks prior to enrollment
Has received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1)
Has received a live vaccine within 30 days of the planned first dose of the study
Receipt of live attenuated vaccination within 30 days prior to first dose of MEDI4736
Any non-oncology live or attenuated vaccine therapy used for prevention of infectious diseases within 30 days prior to the first dose of tremelimumab; if patients is enrolled, patient should not receive live vaccine during the study and 180 days after the last dose of tremelimumab
Vaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Patients planning for a live vaccine
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Live attenuated vaccine within 4 weeks of study drug
Has received a live vaccine within 30 days prior to first dose.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received or will receive a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Receipt of a live vaccine within 4 weeks prior to rituximab administration
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.
Receipt of a live vaccine within 30 days of planned start of study therapy.
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live attenuated vaccine will be required during the study;\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Live-virus vaccination within 30 days prior to day 1 of protocol therapy
Live vaccine ? 6 weeks prior to start of conditioning regimen
Receipt of a live attenuated vaccine within 4 weeks prior to study drug
Receipt of a live vaccine within 30 days of the start of treatment; examples are measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette–Guerin (BCG), oral polio vaccine, and oral typhoid vaccine
Subjects vaccinated with a live (attenuated) vaccine (e.g., FluMist) or a killed (inactivated)/subunit vaccine (e.g., PNEUMOVAX, Fluzone) within 28 days or 14 days, respectively, of the first planned dose of ETBX vaccine
Administration of attenuated vaccine within 4 weeks before enrollment
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab
Patients must not have live vaccine therapies for prevention of infectious diseases within 28 days of first nivolumab dose
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Vaccination with a live virus vaccine or live attenuated vaccine within 28 days prior to D1C1
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP
Received a live vaccine within 30 days of the first dose of study medication
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Administration of a live, attenuated vaccine within 4 weeks before treatment start or anticipation that such a live attenuated vaccine will be required during the study; influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to treatment start or at any time during the study
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received a live vaccine within 30 days of planned start of study medication
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
The participant has received a live vaccine within 30 days prior to the first dose of trial treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Vaccination with a live vaccine < 28 days prior to the start of treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to trial registration.
Live vaccine within 30 days of planned start of study therapy
Treatment with live vaccine within 30 days prior to the first dose of study medication are not eligible
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received a live vaccine within 30 days of planned start of study medication
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of study drug
Received a live virus vaccine within 30 days of planned start of study treatment
Vaccination with a live vaccine a minimum of 30 days prior to study treatment
Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product;
Has received a live vaccine within 30 days prior to the radiation therapy
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Administration of a live, attenuated vaccine within 4 weeks prior to randomization
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received a live virus vaccine within 30 days of planned start of trial treatment
Received live vaccine within 30 days of planned start of study therapy
Live vaccine within 30 days of planned start of study therapy
Vaccination with a live vaccine within 28 days of the initiation of treatment
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products )
Receipt of live, attenuated vaccine within 30 days prior to the first dose of MEDI4736
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Vaccination with a live vaccine within 28 days prior to randomization
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 Exclusion Criteria Unique to Cobimetinib:
Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment.
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study
Has received live vaccine within 30 days of the planned start of study therapy
Non-oncology vaccine therapies for prevention of infection disease (e.g. seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of study drug administration. Vaccination while on study is also prohibited except for administration of the inactivated influenza vaccine.
Immunization with any attenuated live vaccine within 1 week prior to registration
Subjects who have received live virus vaccination within the 4 weeks prior to planned initiation of study treatment
Patients who had received one or more doses of the pneumococcal polysaccharide vaccine (PPSV)23 vaccine in the previous 12 months
Vaccination with a live vaccine within 28 days prior to randomization
Unwilling to avoid vaccinations with live vaccine and concomitant use of attenuated live vaccines
Has received a live vaccine within 30 days prior to the first dose of study drug
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab\r\n* Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Has received a live vaccine within 30 days prior to the first dose of study treatment
Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted
Live vaccination within 4 weeks of the first dose of avelumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab (MEDI4736) or tremelimumab
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days of the first dose of study treatment.
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Received a live vaccine within 30 days of planned start of study treatment
Vaccination with a live vaccine a minimum of 28 days prior to randomization
Live or attenuated vaccines (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551
Participation in a previous vaccine trial
Live vaccine within 30 days prior to registration.
Has received a live vaccine within 30 days prior to first dose of study therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
Patient who have received a live vaccine within 30 days prior to cycle 1 day 1
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.
Have received a live vaccine within 30 days before the first dose of study treatment
Receipt of a live vaccine within 30 days of receipt of study therapy
Participant has received a live vaccine within 2 weeks (less than 14 days) prior to C1D1
Subject has received a live vaccine within 4 weeks prior to C1D1
Any patient receiving a live vaccine must allow a 4-week interval before starting treatment on this study
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Live attenuated vaccinations 14 days prior to treatment
Vaccination with a live-virus vaccine up to 4 weeks prior to onset of study treatment.
Receipt of a live (attenuated) vaccine within 1 month prior to Screening
Administration of a live/attenuated vaccine within 4 weeks prior to the first dose of study treatment, within 5 months following the administration of the last dose of study drug, or anticipation that such a live/attenuated vaccine will be required during the study
Administration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the study
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study
Has received a live vaccine within 30 days of planned start of study therapy.
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1
Has received a live vaccine within 30 days prior to the planned first dose of study therapy.
Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment
Administration of live, attenuated vaccine within 8 weeks before the start of treatment (day 0) and throughout the study
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Receipt of a live vaccine within 30 days of receipt of study therapy
No receipt of a live vaccine within 4 weeks prior to registration
Vaccination with a live vaccine a minimum of 28 days prior to the start of Cycle 1
Participant has received a live vaccine within 4 weeks prior to screening
Any plan to receive a live attenuated vaccine during study treatment
Patient who received a live vaccine within 30 days of planned start of study therapy
Patient who received a live vaccine within 30 days of planned start of study therapy
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Any non-oncology live viral vaccine therapies used for the prevention of infectious diseases.
Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization
Received live vaccine within 28 days prior to enrollment
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Prior treatment with a cancer vaccine
Received a live vaccine within 30 days prior to day 1
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
Immunization with a live/attenuated vaccine within 28 days prior to conditioning
Receipt of live vaccine within 4 weeks prior to study drug administration
Has received a live vaccine within 30 days prior to first dose
Has received a live vaccine within 28 days of planned start of study therapy
Has received a live vaccine within 30 days prior to the first dose of study therapy
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab; for example, the intramuscular influenza vaccine can be administered but the intranasal vaccine is a live attenuated virus that cannot be given
Administration of a live, attenuated vaccine within 4 weeks for first study treatment
Receipt of any live vaccine within 4 weeks prior to first dose of study treatment.
Women who have received typhoid vaccine within three years or any other vaccine within three months will be excluded
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Has received a live vaccine within 30 days prior to the first dose of study treatment
Immunization with a live, attenuated vaccine within 4 weeks prior to study enrollment
Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.
Vaccination with live attenuated vaccine within 28 days prior to day 1 of PROSTVAC-V/F administration or vaccination with a killed vaccine within 14 days prior to day 1 of PROSTVAC-V/F
3. Administration of any vaccine within 4 weeks of the first study treatment
Administration of any vaccine within 8 weeks of enrollment and within 4 weeks for flu vaccine.
Live attenuated vaccine within 4 weeks prior to first day of study treatment
Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab; inactivated vaccines, such as the injectable influenza vaccine, are permitted
Planned administration during the study of a HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine.
Administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
Inclusion Criteria:\n\n        Study entry (enrollment) occurs at the Pre-vaccination visit.\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol.\n\n          -  Written informed consent obtained from the subject.\n\n          -  A male or female aged 18 years or older at the time of study entry.\n\n          -  Has undergone or will undergo autologous HCT within 50-70 days prior to the first\n             vaccination with the study vaccine/placebo, and there are no plans for additional\n             HCTs.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study. For this\n             study population, non-childbearing potential is defined as current tubal ligation,\n             hysterectomy, ovariectomy or post-menopause.\n\n        OR Female subjects of childbearing potential may be enrolled in the study, if the subject\n        has practiced adequate contraception for 30 days prior to vaccination with the study\n        vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has\n        agreed to continue adequate contraception during the entire treatment period and for 12\n        months after completion of the vaccination series (i.e., until Month 13).\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine/placebo, or planned use\n             during the study period. However, the investigational use of a registered or\n             non-registered product to treat the subject's underlying disease for which the HCT was\n             undertaken, or a complication of the underlying disease, is allowed.\n\n          -  Previous vaccination against HZ or varicella within the 12 months preceding the first\n             dose of study vaccine/placebo.\n\n          -  Planned administration during the study of a HZ vaccine other than the study vaccine.\n\n          -  Occurrence of a varicella or HZ episode by clinical history within the 12 months\n             preceding the first dose of study vaccine/placebo.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccine or study material and equipment.\n\n          -  Prophylactic antiviral therapy with activity against Varicella Zoster Virus (VZV)\n             expected to last more than 6 months after transplantation.\n\n          -  Administration and/or planned administration of a vaccine not foreseen by the study\n             protocol between HCT and 30 days after the last dose of study vaccine/placebo.\n             However, licensed non-replicating vaccines may be administered up to 8 days prior to\n             dose 1and/or 2, and/or at least 14 days after any dose of study vaccine/placebo.\n\n          -  HIV infection by clinical history.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions (if of childbearing potential) before Month 13 (i.e., one year after the\n             last dose of study vaccine/placebo).
A subject previously enrolled in study NCT00294047, who received the control vaccine, and who cannot receive the GSK580299 vaccine because the subject is above the age for which the vaccine is licensed.
Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days (i.e., Day 0-29) of each dose of vaccine, with the exception of administration of routine meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study vaccine. Enrolment will be deferred until the subject is outside of specified window.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Received a live vaccine within 30 days of planned PD-1 start date.
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Subjects must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent.
Receipt of a live, attenuated vaccine within 4 weeks prior to initiation of study drug (cycle 1, day 1 [C1D1]) or anticipation that such a live, attenuated vaccine will be required during the study
Live vaccine ? 4 weeks prior to enrollment
Receipt of live attenuated vaccination within 30 days prior to the first vaccine
Male subjects who are not employing an effective method of birth control from starting vaccine, including dosing interruptions through 90 days after receipt of the last vaccine; refrain from sperm cell donation while receiving vaccination and for at least 90 days after the last vaccine
Has received a live-virus vaccine within 30 days prior to the first dose of study treatment
Administration of a live, attenuated vaccine within 28 days before Day 1 or anticipation that such a live attenuated vaccine will be required during the study
Received a live viral vaccine within 6 months prior to the first dose of study drug.
Received live vaccine within 28 days prior to enrollment.
Has taken any live vaccinations within 30 days before study drug administration except for the influenza vaccine.
Receipt of a live vaccine within 30 days of planned start of study drug.
Non-oncology vaccine therapies for prevention of infectious diseases (example, human papillomavirus [HPV] vaccine) within 4 weeks of study drug administration. The inactivated seasonal influenza vaccine can be given to participants before treatment and while on therapy without restriction. Influenza vaccines containing live virus or other clinically indicated vaccinations for infectious diseases (example, pneumovax, varicella) may be permitted but must be discussed with the sponsor's medical monitor and may require a washout period before and after administration of vaccine.
Has received a live vaccine within 30 days prior to randomization.
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Have received a live vaccination within 30 days of study start.
Prior treatment with a tumor vaccine.
Received live vaccine within 28 days prior to enrollment.
Receipt of a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to first dose of study drug.
Has received a live vaccine within 30 days prior to the first dose of trial treatment